Google
ABBV 株価分析 — ABBVIE INC (Healthcare >> Drug Manufacturers - General)
ABBV に関するよくある質問
ABBVのPER（株価収益率）は？
ABBVIE INC（ABBV）は現在PER 124.98倍で取引されています。
ABBVのROE（自己資本利益率）は？
ABBVIE INCのROEは-55.04%です。
ABBVの配当利回りは？
ABBVIE INCの配当利回りは2.56%です。
ABBVの品質スコア（Quality Score）は？
当社のAIはABBVの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ABBVは今が買い時ですか？
当社AIのタイミングスコアは100点中87点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ABBVはどのセクターに属しますか？
ABBVIE INCはHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NYSE市場）
ABBV AI Analysis Summary
Our AI summary for ABBV: ABBVIE INC (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 124.98, ROE of -55.04%, a dividend yield of 2.56%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 250.94
Price
-6.47
(-2.51%)
Day Change
|
|
|---|
ABBV, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
2769
|
| Magic Formula Rank by ROE |
2769
|
| Magic Formula Rank by ROIC |
2728
|
| Price | 250.94 |
| PBV / Sector |
-68.78 / 2.68
|
| Earning Per Share | 2.01 |
| PE / Sector |
124.98 / 27.65
|
| PEG or PE/Growth / Sector |
-5.20 / 0.28
|
| Average 1M Daily Value |
1,190.30 M
GREAT
|
| Average 1W Daily Value |
1,351.73 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
66% |
| 配当 |
|
12% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:25 |
| Symbol | ABBV |
| Name | ABBVIE INC |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 1,766.79 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 454,790.15 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
Phone: 847 932 7900
Website: https://www.abbvie.com
Employees: 57,000
Description: AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
